Incurred healthcare costs over one year*
* Using a Markov model with base case model assumptions.
† 2016 US dollars.
|Mearns ES, et al. (2017)24|
|Objective||Assess the cost-effectiveness and economic impact of enzymatic debridement with SANTYL Ointment vs autolytic debridement with medicinal honey for PU treatment in the HOPD setting.|
|Primary endpoint||Calculate incurred costs over one year for each study group|
|Secondary endpoint||Determine QALWs for each study group|
Study results cannot be generalized to:
|Number of subjects
(with stage III and IV PUs treated in the HOPD setting)
446 SANTYL Ointment-treated patients‡
341 Medicinal honey-treated patients‡
Total number of PUs: 517 in each group, with the majority being stage III or IV
Markov model§ with base case analysis of adult patients (≥18 years) with PUs treated in a HOPD|| and budget impact model over a time horizon of one year
Three health states¶:
‡ From US World Registry (USWR).
§ Constructed from a US payer perspective and assessed all costs in 2016 US dollars.
|| All patients entered the model in the inflammation/senescence health state and could fail to progress clinically, achieve 100% granulation, or achieve epithelialization during any of the one-week cycles.
¶ Transition probabilities were based on the observed rates from an analysis of patients from the USWR.
Important Safety Information:Use of SANTYL Ointment should be terminated when debridement is complete and granulation tissue is well established.
One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone. Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound.